Trial NCT05033847
Publication Al Kaabi N, Sig Transduct Target, 2022
Primary outcome on the report: The comparative assessment of immunogenicity between heterologous and homologous booster vaccinations on 14 and 28 days after the boost.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.